Baxter International Inc. furnished a Stockholder Engagement Presentation as Exhibit 99.1 under Item 7.01, detailing CEO appointment, leadership transitions, board refreshment, FY 2025 financial snapshot from continuing operations, and strategic priorities. The information is not deemed filed under the Exchange Act.
Key takeaways
Andrew Hider appointed President and CEO in August 2025 following robust search process
Brent Shafer serving as Non-Executive Chair after separation of CEO and Chair roles
Divestiture of Vantive Kidney Care segment completed in January 2025